Sarepta Reports Strong Preliminary Full-Year 2025 Revenue & Robust Cash Position; Reaffirms ELEVIDYS Sales Floor
SRPT has more than doubled off its 52-week low of $10.415.
Summary
Sarepta Therapeutics reported strong preliminary full-year 2025 net product revenues of $1.86 billion, driven by ELEVIDYS and PMO franchises, and ended the year with a robust cash balance of $953.8 million.
Key Events · Earnings and Guidance · SRPT
-
Preliminary Full-Year 2025 Revenue
Sarepta reported preliminary total net product revenue of $1.86 billion for the full year 2025.
-
ELEVIDYS Performance
Preliminary ELEVIDYS net product revenue reached $898.7 million for the full year 2025, despite Q4 revenue of $110.4 million being impacted by the year-end flu season and rescheduled patient infusions.
-
PMO Franchise Strength
The PMO net product revenues contributed $965.6 million for the full year 2025.
-
Strong Cash Position
The company ended 2025 with approximately $953.8 million in cash, cash equivalents, restricted cash, and investments, reflecting positive cash flow.
Analysis · SRPT · Life Sciences
This 8-K filing provides a significant preliminary financial update ahead of the J.P. Morgan Healthcare Conference, offering investors an early look at Sarepta's strong 2025 performance. The reported full-year net product revenue of $1.86 billion, with ELEVIDYS contributing nearly $900 million, demonstrates robust commercial execution for its key therapies. The substantial cash balance of $953.8 million, achieved through positive cash flow, provides significant financial flexibility for continued investment in its pipeline and approved therapies. While fourth-quarter ELEVIDYS revenue was lower than the full-year average, the company attributed this to temporary, external factors like the flu season and rescheduled infusions, which helps mitigate concerns. The reconfirmation of a $500 million sales floor for ELEVIDYS in 2026 signals management's confidence in the product's continued growth trajectory. Investors should view this as a positive indicator of the company's financial health and operational stability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRPT was trading at $21.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.42 to $128.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.